TLR9 and amyloidosis: In our initial studies, we utilized type B CpG ODN to stimulate innate immunity via TLR9 in the Tg2576 AD mouse model and showed this to be highly effective at reducing parenchymal and vascular amyloid burden, correlating with behavioral improvements [9].